effectively by injection, but a pharmaceutically acceptable material means for administering morphine orally as an analgesic, as an adjunct to anesthesia, as an antitussive, and a nonspecific antidiarrheal therapy appears to be lacking in the pharmaceutical and medical arts.

Ultra low doses of antibodies to morphine are known. Beregovoi, et al., *Effect of antibodies to morphine in ultralow doses on induction of long-term potentiation in hippocampal slices from rats with chronic morphine dependence,* Bull Exp Biol Med. 2003 Jan;135 Suppl 7:26-8.

There is a continuous need for new treatment for respiratory disorders and cough.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 – Shows the changes in night coughing intensity evaluated based on Cough intensity scale, changes in mean score I groups (%)

FIG. 2 – Shows the changes in daytime coughing intensity evaluated based on Cough intensity scale, changes in mean score I groups (%).

SUMMARY

The present ~~invention~~disclosure is concerned with a composition and method for treating and preventing upper respiratory tract conditions or disorders and the symptoms associated therewith.

In one aspect of the present disclosure, there is provided a combination pharmaceutical composition comprising a) homeopathically activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

In one ~~aspect~~embodiment, the ~~invention~~present disclosure provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

In one variant, the present ~~invention~~disclosure provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine, wherein the antibody is to the entire bradykinin or fragments thereof.

In one variant, the present ~~invention~~disclosure provides a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine, wherein the antibody is to the entire histamine or fragments thereof.

In one variant, the combination pharmaceutical composition of this ~~aspect~~embodiment of the ~~invention~~present disclosure includes activated-potentiated form of an antibody to bradykinin is in the form of a mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions impregnated onto a solid carrier. The activated-potentiated form of an antibody to histamine is in the form of mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions may be subsequently impregnated onto the solid carrier. The activated-potentiated form of an antibody to morphine is in the *form of mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions may* be subsequently impregnated onto the solid carrier.

In one variant, the combination pharmaceutical composition of this ~~aspect~~embodiment of the ~~invention~~present disclosure includes activated-potentiated form of an antibody to histamine is in the form of a mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions impregnated onto a solid carrier. The activated-potentiated form of an antibody to bradykinin is in the form of mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions may be subsequently impregnated onto the solid carrier. The activated-potentiated form of an antibody to morphine is in the form of mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions may be subsequently impregnated onto the solid carrier.

In one variant, the combination pharmaceutical composition of this ~~aspect~~embodiment of the ~~invention~~present disclosure includes activated-potentiated form of an antibody to morphine is in the form of a mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions impregnated onto a solid carrier. The activated-potentiated form of an antibody to bradykinin is in the form of mixture of (C12, C30, and C50) or (C12, C30 and C200) homeopathic dilutions may be subsequently impregnated *onto the solid carrier. The activated-potentiated form of an antibody to histamine is in the* form of mixture of (C12,

C30, and C50) or (C12, C30 and C200) homeopathic dilutions may be subsequently impregnated onto the solid carrier.

Preferably, the activated-potentiated form of an antibody to bradykinin is a monoclonal, polyclonal or natural antibody, more preferably, a polyclonal antibody. In one variant of this ~~aspect~~embodiment of the ~~invention~~present disclosure, the activated-potentiated form of an antibody to bradykinin is prepared by successive centesimal dilutions coupled with shaking of every dilution.

Preferably, the activated-potentiated form of an antibody to histamine is a monoclonal, polyclonal or natural antibody, more preferably, a polyclonal antibody. In one variant of this ~~aspect~~embodiment of the ~~invention~~present disclosure, the activated-potentiated form of an antibody to histamine is prepared by successive centesimal dilutions coupled with shaking of every dilution.

Preferably, the activated-potentiated form of an antibody to morphine is a monoclonal, polyclonal or natural antibody, more preferably, a polyclonal antibody. In one variant of this ~~aspect~~embodiment of the ~~invention~~present disclosure, the activated-potentiated form of an antibody to morphine is prepared by successive centesimal dilutions coupled with shaking of every dilution.

In another ~~aspect~~embodiment, the ~~invention~~present disclosure provides a method of treating a respiratory disease or condition, said method comprising administering to a patient in need thereof a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine. Preferably, the activated-potentiated form of an antibody to bradykinin, the activated-potentiated form of an antibody to histamine and the activated-potentiated form of an antibody to morphine are administered in the form of combined pharmaceutical composition.

In another ~~aspect~~embodiment, the ~~invention~~present disclosure provides a method of treating a patient suffering from respiratory tract disorders or conditions, by administration of a combination pharmaceutical composition wherein the composition comprises a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of *an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.*

In one variant the respiratory tract disorder or condition is viral respiratory tract infection.

In another variant the respiratory tract disorder or condition is acute upper respiratory tract disorder.

In another variant the respiratory tract disorder or condition is chronic upper respiratory tract disorder.

In another ~~aspect~~embodiment, the ~~invention~~present disclosure provides a method of treating a patient suffering from symptoms of upper respiratory tract disorder or condition, by administration of a combination pharmaceutical composition wherein the composition comprises a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

In one variant the symptom of respiratory tract disorder or condition is cough.

In one variant of the ~~invention~~present disclosure, there is provided administration of from one to two unit dosage forms of the activated-potentiated form of an antibody to bradykinin, one to two unit dosage forms of the activated-potentiated form of an antibody to histamine and from one to two unit dosage forms of the activated-potentiated form of an antibody to morphine, each of the dosage form being administered from once daily to four times daily. Preferably, the one to two unit dosage forms of each of the activated-potentiated forms of antibodies is administered twice daily.

In a preferred variant of this ~~aspect~~embodiment of the ~~invention~~present disclosure, there is provided administration of from one to two unit dosage forms, of the combination composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine, each of the dosage form being administered from once daily to four times daily. Preferably, one to two unit dosage forms are administered twice daily.

In another variant of this ~~aspect~~embodiment of the ~~invention~~present disclosure, which is preferred, the combination is administered in the form of one unit dosage form comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine, preferably twice daily.

What is claimed is:

1. A combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

2. The combination pharmaceutical composition of claim 1, wherein the activated-potentiated form of an antibody to bradykinin having SEQ ID NO:1.

3. The combination pharmaceutical composition of claim 1, wherein the activated-potentiated form of an antibody to bradykinin is in the form of a mixture of C12, C30, and C50 homeopathic dilutions impregnated onto a solid carrier and the activated-potentiated form of an antibodies to histamine and an activated-potentiated form of an antibody to morphine are in the form of mixture of C12, C30, and C50 homeopathic dilutions impregnated onto said solid carrier.

4. The combination pharmaceutical composition of claim 3, wherein said carrier is impregnated with a mixture of said dilutions.

5. The combination pharmaceutical composition of claim 1, wherein the activated-potentiated form of an antibody to bradykinin is a monoclonal, polyclonal or natural antibody.

6. The combination pharmaceutical composition of claim 5, wherein the activated-potentiated form of an antibody to bradykinin is a polyclonal antibody.

7. The combination pharmaceutical composition of claim 1, wherein the activated-potentiated form of an antibody to histamine is a monoclonal, polyclonal or natural antibody.

8. The combination pharmaceutical composition of claim 7, wherein the activated-potentiated form of an antibody to histamine is a polyclonal antibody.

9. The combination pharmaceutical composition of claim 1, wherein the activated-potentiated form of an antibody to morphine is a monoclonal, polyclonal or natural antibody.

10. The combination pharmaceutical composition of claim 9, wherein the activated-potentiated form of an antibody to morphine is a polyclonal antibody.

11. The combination pharmaceutical composition of claim 1, wherein said activated-potentiated forms of antibodies prepared by successive centesimal dilutions coupled with shaking of every dilution.

12. A method of treating a respiratory disease or condition, said method comprising administering to a patient in need thereof, substantially at the same time a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

13. The method of claim 12, wherein said activated-potentiated forms of antibodies are administered in the form of a combination pharmaceutical composition.

14. The method of claim 13, wherein said respiratory disease or condition is acute.

15. The method of claim 13, wherein said respiratory disease or condition is chronic.

16. The method of claim 13, wherein said respiratory disease or condition is respiratory infection.

17. The method of claim 16, wherein said respiratory infection is viral respiratory infection.

18. The method of claim 13, wherein said combination pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage form being administered from once daily to four times daily.

19. The method of claim 13, wherein said combination pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage form being administered twice daily.

20. A method of treating a patient suffering from symptoms of upper respiratory tract disorder or condition, said method comprising administering to a patient in need thereof a combination pharmaceutical composition which comprises a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

21. The method of claim 20, wherein said symptom of respiratory tract disorder or condition is cough.

22. The method of claim 21, wherein cough is reduced as measured by the cough intensity scale.

23. The method of claim 21, wherein the combination pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage form being administered from once daily to four times daily.

24. The method of claim 21 wherein the combination pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage form being administered twice daily.

25. A pharmaceutical composition for use in treating a patient suffering from a respiratory disease or condition, said composition having been obtained by providing a) an activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine, each prepared by consecutive repeated dilution and multiple shaking of each obtained solution in accordance with homeopathic technology, and then either combining the potentiated solutions by mixing them, or, alternatively, impregnating a carrier mass with said combined solution or with the solutions separately.

What is claimed is:

1. A combination pharmaceutical composition comprising a) homeopathically activated-potentiated form of an antibody to bradykinin, b) an activated-potentiated form of an antibody to histamine and c) an activated-potentiated form of an antibody to morphine.

2. The combination pharmaceutical composition of claim 1, wherein the homeopathically activated-potentiated form of the antibody to bradykinin having SEQ ID NO:1.

3. The combination pharmaceutical composition of claim 1, wherein the homeopathically activated-potentiated form of the antibody to bradykinin is in the form of a mixture of C12, C30, and C50 homeopathic dilutions impregnated onto a solid carrier and the homeopathically activated-potentiated form of the antibodies to histamine and the homeopathically activated-potentiated form of the antibody to morphine are in the form of mixture of C12, C30, and C50 homeopathic dilutions impregnated onto said solid carrier.

4. The combination pharmaceutical composition of claim 3, wherein said carrier is impregnated with a mixture of said dilutions.

5. The combination pharmaceutical composition of claim 1, wherein the homeopathically activated-potentiated form of the antibody to bradykinin is a monoclonal, polyclonal or natural antibody.

6. The combination pharmaceutical composition of claim 5, wherein the homeopathically activated-potentiated form of the antibody to bradykinin is a polyclonal antibody.

7. The combination pharmaceutical composition of claim 1, wherein the homeopathically activated-potentiated form of the antibody to histamine is a monoclonal, polyclonal or natural antibody.

8. The combination pharmaceutical composition of claim 7, wherein the homeopathically activated-potentiated form of the antibody to histamine is a polyclonal antibody.

9. The combination pharmaceutical composition of claim 1, wherein the homeopathically activated-potentiated form of the antibody to morphine is a monoclonal, polyclonal or natural antibody.

10. The combination pharmaceutical composition of claim 9, wherein the homeopathically activated-potentiated form of the antibody to morphine is a polyclonal antibody.

11. The combination pharmaceutical composition of claim 1, wherein said homeopathically activated-potentiated forms of antibodies prepared by successive multiple dilutions in a solvent selected from the group comprising water and a mixture of water and ethanol, coupled with shaking of every dilution.